JANX Stock Price
JANX
JANX stock price is $17.47 (-2.02% on the day), giving JANX a market cap of $1.07B. Below are the price chart, the MarketXLS Rank, the company profile and the latest news.
JANX Stock Overview
- Price
- $17.47
- Previous close
- $17.83
- Open
- $17.93
- Market cap
- $1.07B
- 1-year price target
- $30.94
- MarketXLS Rank
- 43
About JANX
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | JANX | $17.47 | -2.0% | 540.00K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |